MedTech Dive June 30, 2023
Dexcom announced plans last week to create a new type of continuous glucose monitor (CGM) for people who don’t take insulin at the American Diabetes Association’s Scientific Sessions. The new device builds on the company’s growth strategy that includes broader coverage of its existing CGMs, with Medicare earlier this year expanding reimbursement of the devices to people who take basal, or daily, insulin. Dexcom also raised its 2025 revenue forecast last week to a range of $4.6 billion to $5.1 billion, up from its previous projection of $4 billion to $4.5 billion.
Teri Lawver, Dexcom’s new chief commercial officer, will be leading this strategy. Lawver joined the company in January for the newly created role after two decades at...
Today's Sponsors
Today's Sponsor